Helicobacter pylori treatment results in Slovenia in the period 2013-2015 as a part of European Registry on Helicobacter pylori Management

Abstract

Introduction. Helicobacter pylori ( H pylori ) is the most common chronic bacterial infection in the world affecting over 50% of the world’s population. H pylori is a grade I carcinogen,   responsible for the development of 89 % of non-cardia gastric cancers.

Patients and methods. Slovenia is a part of the European Registry on Helicobacter pylori Management from the beginning.  In seven medical institutions data for H pylori eradication treatments was collected for 1774 patients from April 16^th 2013 to May 15^th 2016. 1519 patients were eligible for further modified intention to treat ( mITT ) analysis and 1346 patients for per protocol ( PP ) analysis.

Results. Patients drop out was 11,4 %. Eradication rate for  7 day triple therapy with proton pump inhibitor ( PPI ) + Clarithromycin ( C ) + Amoxicillin (A) was 88,7 % PP and 72,0% mITT; for PPI + C + Metronidazole (M)  85,2 % PP and 84,4 % mITT. Second line14 day therapy PPI + A + Levofloxacin  had 92,3 % eradication rate PP and 87,1%  mITT. Ten to fourteen day Bismuth quadruple therapy was the  therapy in difficult to treat patients.  At the end all patients that adhered to prescribed regimens were cured of their H pylori infection.

Conclusion. High drop out rate  deserves further analysis. Slovenia is still a country with < 15 % Helicobacter pylori resistance to clarithromycin, triple therapy with PPI plus two antibiotics reaches PP eradication rate > 85 %, but mITT eradication rates are suboptimal.